Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund (BIVF) is the corporate venture arm of pharma group Boehringer Ingelheim, launched in 2010 and headquartered in Ingelheim am Rhein, Germany. It runs a 350 million euro evergreen fund investing globally (EU, US, China) as a dedicated Seed/Series A biotech investor, backing first-in-class disease-modifying therapeutics across immuno-oncology, regenerative medicine, auto-immunity, anti-infectives (AMR) and digital health. It typically takes a minority stake with a board seat, has invested in over 70 companies, and has produced multiple exits including six acquisitions by its own parent.
Key facts
Recent exits
Coverage notes
1 fund tracked, 42 portfolio companies (30 active · 12 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
42 companiesFunds & portfolio
Every fund Boehringer Ingelheim Venture Fund has raised, with its portfolio companies. Hand-checked from public filings.
Boehringer Ingelheim Venture FundEvergreenActive2010 · 16yr€350M30 active · 12 realized
Unrealized
30 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Germany | 2019 | |
| Biotech | Germany | 2012 | |
| HealthTech | Germany | 2020 | |
| Biotech |  US | 2021 | |
| Biotech |  Sweden | 2021 | |
| Biotech |  France | 2023 | |
| HealthTech | US | 2020 | |
| HealthTech |  UK | 2018 | |
| HealthTech |  Portugal | 2022 | |
| Biotech | UK | 2022 | |
| Biotech | France | 2020 | |
| Biotech | UK | 2023 | |
| Biotech | Germany | 2016 | |
| Biotech | US | 2020 | |
| Biotech | Singapore | 2021 | |
| Biotech |  Belgium | 2023 | |
| Biotech | US | 2024 | |
| Biotech |  Austria | 2020 | |
| Biotech | Germany | 2024 | |
| Biotech | Belgium | 2017 | |
| Biotech | US | 2019 | |
| Biotech | China | 2021 | |
| Biotech | UK | 2019 | |
| Biotech | Germany | 2021 | |
| Biotech | US | 2021 | |
| Biotech |  Switzerland | 2024 | |
| Biotech | China | 2024 | |
| Biotech | Germany | 2019 | |
| Biotech | Switzerland | 2023 | |
| Biotech | Germany | 2017 |
Germany· Entry 2019Germany· Entry 2012Germany· Entry 2020US· Entry 2021Sweden· Entry 2021France· Entry 2023US· Entry 2020UK· Entry 2018Portugal· Entry 2022UK· Entry 2022France· Entry 2020UK· Entry 2023Germany· Entry 2016US· Entry 2020Belgium· Entry 2023US· Entry 2024Austria· Entry 2020Germany· Entry 2024Belgium· Entry 2017US· Entry 2019UK· Entry 2019Germany· Entry 2021US· Entry 2021Switzerland· Entry 2024Germany· Entry 2019Switzerland· Entry 2023Germany· Entry 2017Realized
12 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | Belgium | 2019 | 2026 | IPO | – | – | |
| Biotech | Switzerland | 2016 | 2019 | Trade Sale | – | ||
| Biotech | US | 2014 | 2020 | Trade Sale | – | ||
| Biotech | Austria | 2013 | 2019 | IPO | – | – | |
| Biotech | France | 2017 | 2025 | Trade Sale | – | ||
| Biotech | Switzerland | 2013 | 2020 | Trade Sale | – | ||
| Biotech | Switzerland | 2011 | 2013 | Trade Sale | – | ||
| Biotech | Germany | 2014 | 2017 | Trade Sale | – | ||
| HealthTech |  Spain | 2013 | 2018 | Trade Sale | – | ||
| Biotech | Switzerland | 2019 | 2023 | Trade Sale | – | ||
| Biotech | US | 2016 | 2019 | Trade Sale | – | ||
| Biotech | Austria | 2013 | 2018 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€350M
Germany·€315M
Germany·€300M
Germany·€400M
Germany·€400M
Germany·€300M
Germany·€300M
Germany·€400M
Germany·€400M
Germany·€300M
Germany·€283M
Germany·€277MGet the full picture on Boehringer Ingelheim Venture Fund.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in